Sun Pharmaceutical Industries Ltd Stock Price Today (NSE: SUNPHARMA)
Fundamental Score
Sun Pharmaceutical Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sun Pharmaceutical Industries Ltd share price today is ₹1905.80, up +1.47% on NSE/BSE as of 18 May 2026. Sun Pharmaceutical Industries Ltd (SUNPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.34L (Cr). The 52-week high for SUNPHARMA share price is ₹1885.80 and the 52-week low is ₹1548.00. At a P/E ratio of 37.57x, SUNPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.86% and a debt-to-equity ratio of 0.07.
Sun Pharmaceutical Industries Ltd Share Price Chart — NSE/BSE Historical Performance
Sun Pharmaceutical Industries Ltd share price chart: 1.22% return over the past month. 52-week high ₹1885.80, 52-week low ₹1548.00.
Sun Pharmaceutical Industries Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1845.70 | ₹1860.00 | ₹1820.00 | ₹1824.80 | 19.72L (Cr) | |
| ₹1875.00 | ₹1879.40 | ₹1840.00 | ₹1845.70 | 32.63L (Cr) | |
| ₹1827.20 | ₹1885.80 | ₹1825.00 | ₹1872.70 | 25.65L (Cr) | |
| ₹1822.00 | ₹1857.50 | ₹1819.20 | ₹1847.90 | 28.38L (Cr) | |
| ₹1850.20 | ₹1857.10 | ₹1826.30 | ₹1834.40 | 22.01L (Cr) | |
| ₹1837.00 | ₹1857.80 | ₹1818.40 | ₹1850.20 | 32.47L (Cr) | |
| ₹1828.50 | ₹1831.70 | ₹1798.60 | ₹1820.80 | 30.11L (Cr) | |
| ₹1820.00 | ₹1841.00 | ₹1810.00 | ₹1823.50 | 42.06L (Cr) | |
| ₹1771.00 | ₹1815.00 | ₹1761.40 | ₹1808.30 | 47.50L (Cr) | |
| ₹1756.00 | ₹1789.80 | ₹1750.00 | ₹1778.70 | 98.09L (Cr) |
Sun Pharmaceutical Industries Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1820.00 | ₹1885.80 | ₹1798.60 | ₹1824.80 | +0.26% | |
| ₹1762.10 | ₹1815.00 | ₹1613.60 | ₹1808.30 | +2.62% | |
| ₹1712.00 | ₹1843.00 | ₹1712.00 | ₹1757.20 | +2.64% | |
| ₹1634.00 | ₹1792.20 | ₹1598.20 | ₹1737.00 | +6.30% | |
| ₹1720.00 | ₹1806.60 | ₹1583.70 | ₹1595.30 | -7.25% | |
| ₹1841.00 | ₹1849.00 | ₹1707.00 | ₹1719.70 | -6.59% | |
| ₹1688.20 | ₹1833.00 | ₹1667.00 | ₹1831.60 | +8.49% | |
| ₹1611.90 | ₹1722.00 | ₹1600.00 | ₹1690.70 | +4.89% | |
| ₹1599.00 | ₹1668.10 | ₹1548.00 | ₹1594.30 | -0.29% | |
| ₹1690.00 | ₹1695.00 | ₹1567.60 | ₹1594.50 | -5.65% | |
| ₹1675.70 | ₹1748.00 | ₹1647.00 | ₹1706.70 | +1.85% | |
| ₹1679.00 | ₹1727.50 | ₹1636.00 | ₹1675.70 | -0.20% |
Compare SUNPHARMA with Peers:
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sun Pharmaceutical Industries Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Shareholding Pattern
Promoter Holding
% shares held by company founders/management
FII Holding
% shares held by foreign institutional investors
DII Holding
% held by domestic mutual funds, LIC, banks
Promoter Pledged %
% of promoter shares pledged as collateral — lower is safer
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sun Pharmaceutical Industries Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUNPHARMA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (16.86%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.21%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (26.95%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (23.78% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (23.78% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (57.54x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹37510.74 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.48%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 36.67%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Sun Pharmaceutical Industries Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sun Pharmaceutical Industries Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sun Pharmaceutical Industries LtdSun Pharmaceuti...Selected✓ SUNPHARMA • 524715 | 65.2/100 | ₹1905.80₹1906 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6651.00₹6651 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4275.10₹4275 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1333.70₹1334 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1271.20₹1271 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2343.30₹2343 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹912.25₹912 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2319.50₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1428.10₹1428 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5403.00₹5403 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 65/100 | ₹25305.00₹25305 | ₹63358.16₹63358.16 | 41.99Average 42.0 Average | 35.68%Excellent 35.68% Excellent | 46.25%Excellent 46.25% Excellent | 0.05Excellent 0.1 Excellent | 18.98%Excellent 18.98% Excellent | 9.38%Good 9.38% Good | 1.59% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
- Lupin Ltd share price95148.15 Cr
Sun Pharmaceutical Industries Ltd Financial Statements
Comprehensive financial data for Sun Pharmaceutical Industries Ltd including income statement, balance sheet and cash flow
About SUNPHARMA (Sun Pharmaceutical Industries Ltd)
Sun Pharmaceutical Industries Ltd. is a global pharmaceutical powerhouse, forging a path of innovation and accessibility in the healthcare landscape. Emerging from humble beginning...s, the company has evolved into a leading entity, dedicated to the development, manufacturing, and distribution of a wide array of pharmaceutical products. Sun Pharma's unwavering commitment to research and development fuels the creation of novel formulations and therapeutic solutions, addressing critical medical needs across diverse populations. The company operates with a core philosophy of making high-quality medicines available and affordable, ensuring that healthcare reaches a broader spectrum of individuals, globally. The bedrock of Sun Pharma's success lies in its expansive portfolio, which encompasses both branded and generic medications, alongside a robust production of active pharmaceutical ingredients (APIs). This diversified approach allows the company to cater to a multitude of medical conditions, offering effective treatments for ailments affecting various systems within the human body. From central nervous system disorders and cardiovascular issues to metabolic diseases and gastrointestinal complications, Sun Pharma provides solutions in a range of therapeutic areas. Furthermore, its specialized focus on areas such as dermatology, ophthalmology, and oncology highlights the company's commitment to addressing complex and specialized healthcare challenges. Sun Pharma's global footprint is a testament to its ambition and strategic vision, with a significant presence in key markets like India and the United States, as well as an expanding reach across international territories. This expansive network enables the company to efficiently distribute its products, ensuring that healthcare providers and patients have access to the medicines they require. Through strategic partnerships, acquisitions, and a dedication to quality manufacturing practices, Sun Pharma continues to strengthen its position as a global leader in the pharmaceutical industry, driven by a desire to improve lives and make a meaningful contribution to global health.
Company Details
Key Leadership
Corporate Events
Latest News
SUNPHARMA Share Price: Frequently Asked Questions
What is the current share price of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) trades at ₹1905.80 on NSE and BSE. Market cap ₹4.34L (Cr). Educational data only.
What is the P/E ratio of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a P/E of 37.57x vs industry average 31.77x.
What is the Bull Run score for Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a Bull Run score of 65.2/100 based on 25+ financial parameters.
Does Sun Pharmaceutical Industries Ltd pay dividends?
Sun Pharmaceutical Industries Ltd has a dividend yield of 0.89%. Past dividends don't guarantee future payments.
What is the ROE of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has ROE of 16.86%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has debt-to-equity of 0.07.
Is Sun Pharmaceutical Industries Ltd a good investment?
Bull Run gives Sun Pharmaceutical Industries Ltd a score of 65.2/100. This is not investment advice — consult a SEBI-registered advisor.